2020 version platform Search Results


evidence platform® (2020) version r4.2  (Aetion Inc)
90
Aetion Inc evidence platform® (2020) version r4.2
Baseline characteristics in the prespecified study period and post hoc extension study period
Evidence Platform® (2020) Version R4.2, supplied by Aetion Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/evidence platform® (2020) version r4.2/product/Aetion Inc
Average 90 stars, based on 1 article reviews
evidence platform® (2020) version r4.2 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
integrator system (vis) platform version 2020.09.0.8195  (Visiopharm AS)
90
Visiopharm AS integrator system (vis) platform version 2020.09.0.8195
Baseline characteristics in the prespecified study period and post hoc extension study period
Integrator System (Vis) Platform Version 2020.09.0.8195, supplied by Visiopharm AS, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/integrator system (vis) platform version 2020.09.0.8195/product/Visiopharm AS
Average 90 stars, based on 1 article reviews
integrator system (vis) platform version 2020.09.0.8195 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Baseline characteristics in the prespecified study period and post hoc extension study period

Journal: Respiratory Research

Article Title: Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score–matched cohort analysis

doi: 10.1186/s12931-021-01776-y

Figure Lengend Snippet: Baseline characteristics in the prespecified study period and post hoc extension study period

Article Snippet: All analyses were conducted using the Aetion Evidence Platform® (2020) version R4.2. (Aetion Inc., New York, NY, USA), a software platform for real-world data analysis, which has been validated for a range of studies [ ].

Techniques: Medications, Reflux

Escalation to triple therapy (fixed-dose or any concurrent ICS/LAMA/LABA) during each study period

Journal: Respiratory Research

Article Title: Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score–matched cohort analysis

doi: 10.1186/s12931-021-01776-y

Figure Lengend Snippet: Escalation to triple therapy (fixed-dose or any concurrent ICS/LAMA/LABA) during each study period

Article Snippet: All analyses were conducted using the Aetion Evidence Platform® (2020) version R4.2. (Aetion Inc., New York, NY, USA), a software platform for real-world data analysis, which has been validated for a range of studies [ ].

Techniques:

Kaplan–Meier curves of escalation to triple therapy (fixed-dose or concurrent LAMA/LABA/ICS) for the hdPS-matched cohort. Data are shown for the prespecified study period (1 April 2015 to 31 March 2019) ( a ) and the post hoc extension period (1 April 2015 to 31 March 2020) ( b ). CI confidence interval, hdPS high-dimensional propensity score, HR hazard ratio, ICS inhaled corticosteroid, LABA long-acting β 2 -agonist, LAMA long-acting muscarinic antagonist, Tio tiotropium, Tio/Olo tiotropium/olodaterol

Journal: Respiratory Research

Article Title: Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score–matched cohort analysis

doi: 10.1186/s12931-021-01776-y

Figure Lengend Snippet: Kaplan–Meier curves of escalation to triple therapy (fixed-dose or concurrent LAMA/LABA/ICS) for the hdPS-matched cohort. Data are shown for the prespecified study period (1 April 2015 to 31 March 2019) ( a ) and the post hoc extension period (1 April 2015 to 31 March 2020) ( b ). CI confidence interval, hdPS high-dimensional propensity score, HR hazard ratio, ICS inhaled corticosteroid, LABA long-acting β 2 -agonist, LAMA long-acting muscarinic antagonist, Tio tiotropium, Tio/Olo tiotropium/olodaterol

Article Snippet: All analyses were conducted using the Aetion Evidence Platform® (2020) version R4.2. (Aetion Inc., New York, NY, USA), a software platform for real-world data analysis, which has been validated for a range of studies [ ].

Techniques: